Evolus Inc (EOLS)
NASDAQ:EOLS
Want to see EOLS full AI Analyst Report?
EOLS Stock Chart & Stats
$4.53
-$0.47(-4.38%)
At close: 4:00 PM EST
$4.53
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$3.86 - $12.28
Previous CloseN/A
Volume344.54K
Average Volume (3M)1.35M
Market Cap
$301.23M
Enterprise Value$395.89M
Total Cash (Recent Filing)$53.83M
Total Debt (Recent Filing)$155.00M
Price to Earnings (P/E)824.5
Beta0.74
Next Earnings
May 04, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding65,059,990
10 Day Avg. Volume640,904
30 Day Avg. Volume1,354,743
Financial Highlights & Ratios
PEG Ratio6.72
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-9.38
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue1.33
Enterprise Value/Gross Profit2.05
Enterprise Value/Ebitda-14.32
Forecast
1Y Price Target
$14.50Price Target Upside220.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$330.02M
Bulls Say, Bears Say
Bulls Say
International GrowthToxin product gains market share both domestically and internationally while sales outside the United States are becoming a meaningful portion of revenue, supporting revenue diversification and growth.
Product LaunchesLaunch of Evolysse fillers and plans for a broader European product rollout expand the portfolio and have driven a sales pickup, enhancing the company's ability to compete with category leaders.
Profitability And Commercial ProgramsCompany reached profitability and new commercial initiatives such as growth rebates, co-branded marketing, and volume-based pricing drive larger purchases, stronger account retention, and potential margin stability.
Bears Say
Financing Terms RiskAccess to additional debt facilities improves liquidity but the asset-backed revolver's minimum utilization requirement and relatively high interest terms raise financing costs and operational risk.
Guidance And Market SizingManagement's recalibration of long-term outlook and rebased market assumptions indicate a smaller addressable market and slower growth, increasing downside risk to revenue expectations.
Limited New Information And Analyst CautionCompany updates added little beyond prior disclosures and an analyst maintained a Hold while seeking clearer visibility, reducing the likelihood of near-term positive stock movement.
Evolus News
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $3.86 and its highest was $12.28 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $301.23M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is May 04, 2026 which is in 16 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Mar 03, 2026. The company reported $0.044 earnings per share for the quarter, missing the consensus estimate of $0.045 by -$0.001.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is -0.11.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 65,059,990 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of $0.044 in its last earnings report, missing expectations of $0.045. Following the earnings report the stock price went up 35.351%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (220.09% Upside)
$14.50 (220.09% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 424.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.74%
12-Months-Change
Fundamentals
Return on Equity
267.84%
Trailing 12-Months
Asset Growth
-2.88%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive and forward-looking view: strong revenue growth (12% FY, 14% Q4), expanding product portfolio (Jeuveau, Evolysse), improving operating leverage and a clear path to profitability in 2026 supported by disciplined expense control and substantial liquidity. Key challenges include a soft U.S. procedural market (notably fillers), tariff headwinds on Evolysse, elevated GAAP operating expenses, and near-term competitive sampling from new toxin entrants. On balance the company shows momentum and actionable levers to drive profitable growth while acknowledging and modeling the main market and cost risks.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(220.09% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.46% Insiders
9.05% Mutual Funds
33.28% Other Institutional Investors
42.83% Public Companies and
Individual Investors